(0.04%) 5 471.40 points
(0.08%) 39 145 points
(0.36%) 17 781 points
(-0.01%) $80.82
(-3.66%) $2.66
(-0.80%) $2 312.20
(0.18%) $28.92
(3.49%) $1 020.80
(0.27%) $0.936
(0.68%) $10.68
(0.42%) $0.792
(-0.27%) $87.25
Live Chart Being Loaded With Signals
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases...
Stats | |
---|---|
今日成交量 | 577 622 |
平均成交量 | 1.43M |
市值 | 305.15M |
EPS | $-0.410 ( Q4 | 2024-05-08 ) |
下一个收益日期 | ( $-0.350 ) 2024-08-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-1.870 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00900 (0.20%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-20 | Hughes Owen | Buy | 32 500 | Stock Option (Right to Buy) |
2024-06-20 | Bessen Laura | Buy | 32 500 | Stock Option (Right to Buy) |
2024-06-20 | Koppikar Utpal | Buy | 32 500 | Stock Option (Right to Buy) |
2024-06-20 | Downey Bruce | Buy | 32 500 | Stock Option (Right to Buy) |
2024-06-20 | Salter Malcolm | Buy | 32 500 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
60.76 |
Last 97 transactions |
Buy: 4 317 331 | Sell: 1 001 966 |
音量 相关性
C4 Therapeutics, Inc. 相关性
10 最正相关 | |
---|---|
OZEM | 1 |
NBBK | 0.949 |
ICHKX | 0.942 |
EVCGX | 0.937 |
MICFX | 0.937 |
MCHFX | 0.936 |
MMUKX | 0.936 |
MAMA | 0.932 |
PRCNX | 0.931 |
EVUAX | 0.928 |
10 最负相关 | |
---|---|
RAY | -0.925 |
IIMFX | -0.914 |
HTOOW | -0.908 |
QREARX | -0.906 |
NWGL | -0.897 |
CLMB | -0.894 |
HDL | -0.894 |
AAPD | -0.886 |
BRLSW | -0.872 |
GBLMX | -0.865 |
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
C4 Therapeutics, Inc. 相关性 - 货币/商品
C4 Therapeutics, Inc. 财务报表
Annual | 2023 |
营收: | $20.76M |
毛利润: | $13.02M (62.72 %) |
EPS: | $-2.67 |
FY | 2023 |
营收: | $20.76M |
毛利润: | $13.02M (62.72 %) |
EPS: | $-2.67 |
FY | 2022 |
营收: | $31.10M |
毛利润: | $23.52M (75.65 %) |
EPS: | $-2.59 |
FY | 2021 |
营收: | $45.79M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-1.730 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
C4 Therapeutics, Inc.
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。